



WP2 / WP6 – Core Outcome Set Project

DELPHI - Core Outcome Set (COS) definition in

Myeloproliferative Neoplasms (MPN)

December 1st, 2021

INDEX

- A. INTRODUCTION
- B. PROJECT GOALS
- C. METHODS
- D. DELPHI PROCESS
- E. RESULTS AND ANALYSIS
- F. STRENGTH & LIMITATIONS
- G. OUTLOOK

ANNEX 1 PRELIMINARY OUTCOME LIST FOR ALL
ANNEX 2 REFERENCES





A. INTRODUCTION

The HARMONY Alliance is a public-private European Network established in 2017, which includes 53 partners and 43 associated members from 17 countries, including 9 pharmaceutical companies and 9 Patient Umbrella Organizations. One of HARMONY's objectives is to use Big Data to improve understanding and treatment of hematological malignancies (HM) (1). HARMONY Plus is a new public-private partnership within the HARMONY Alliance, launched at 6 October 2020. One of Harmony Plus objectives is to expand the scope of the HARMONY Alliance to cover remaining HM not included in the HARMONY project (2). Just like the previous HARMONY project one work package within HARMONY Plus is focused on defining outcomes sets for further HMs and one outcome set applicable for all HMs. In accordance, this study will be performed to define the core outcome set (COS) in myeloproliferative neoplasms (MPN), one out of four hematological malignancies predefined in HARMONY Plus.

Under the category of myeloproliferative neoplasms (MPNs), the 2016 revised WHO classification includes seven subcategories: polycythemia vera (PV), primary myelofibrosis (PMF) and essential thrombocythemia (ET) among others (3). Common to all is an overproduction of myeloid cells due to a clonal hematopoietic stem cell disorder characterized by an increased risk of thrombosis and progression to acute myeloid leukemia (4). MPN can be diagnosed using blood tests and bone marrow biopsy. MPN are associated with driver mutations in *JAK2*, *CALR* and *MPL* which are crucial for the diagnosis and lead to a constitutive activation of the JAK-STAT signaling (4). In contrast to most myeloid malignancies, MPNs appear to have a remarkably long natural history with many patients with ET and PV having a survival which is like that of the general population. It is therefore important to avoid unnecessary treatment and treatment-related side effects, and all MPNs patients need to be assessed carefully (5). There are therapies for each entity within the heterogeneous group of diseases (6).

Generally valid recommendations of outcomes that should be measured are still missing.

Unfortunately, the ability to compare clinical trials is limited due to differences in their measured outcomes. This lack of standardization relates to the current lack of a COS that can be utilized to guide outcomes selection and harmonization in MPN in current and future trials. For example, measurement of long-term side effects and their influence on the patients' quality of life has not yet been assessed in most of clinical trials.

A COS is a minimum set of outcomes developed by consensus, and a minimum set of outcomes is a reference point and provides the minimum outcomes that should be collected in further clinical trials on a given condition. It is common to develop a COS by consensus by using multi-stakeholder consensus-based Delphi methodology. Use of a COS improves the comparability of clinical trials or other research in real world settings, improves consistency of reporting, reduces selective reporting bias and ensures that appropriate outcomes valued by a range of stakeholders are measured. COS can be incorporated into clinical guidelines and improve the clinical practice and patient outcomes and management.

Key stakeholders who are dedicated to provide their expert feedback are selected based on their skills and experience relevant to the disease or project. The stakeholders include health service users, health service practitioners, researchers, regulators, drug developers, patients and patient advocates. Participants of all stakeholder groups were in particular recruited from members of the HARMONY



work packages, but also participants outside the HARMONY Alliance are welcome to take part of the Delphi survey within their stakeholder group.

In order to ensure that the defined COS is acceptable for each stakeholder group it is important to include as many stakeholders' groups as possible in particular patients and patient advocates to increase the influence of patient groups for the definition of outcomes an additional category is included in the analysis of the Delphi survey, called "patient important". This category will be used in the final analysis to mark a specific outcome as patient important. It is recommended to discuss these specific outcomes separately in the final consensus meeting.

B. PROJECT GOALS

The aim of this project is therefore to define a COS for MPN agreed by consensus of all stakeholder groups and to define standardized outcomes to be measured in future clinical trials and observational studies throughout Europe.

The protocol has been written following the COS-STAP recommendations (7).

C. METHODS

The development of the COS will follow COMET recommendations from the international COS-STAD study (7,8).

To achieve consensus from different stakeholder groups the Delphi method will be used. The Delphi instrument used is an online tool, DelphiManager, provided by the COMET Initiative (9). A more detailed description of the methodology can be found in section D. Recruitment of participants mainly takes place from members of the HARMONY Alliance.

Participants

1. Patients

In this Delphi survey patients equal or older than 18 years with MPN can participate. Different subtypes of MPN are equally included, regardless of previous treatments including stem cell transplantation. Patients treated as outpatients are included as well as patients treated in hospital settings. Due to the use of English for the Delphi survey, participation is limited to patients understanding English.

2. Clinicians and Clinical researchers

Every clinician within or outside the HARMONY Alliance with experiences in MPN can take part in the survey.



3. Drug developers

Participants have been recruited from stakeholder organizations that are members of HARMONY Plus, including European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies.

4. Regulators

Recruitment of participants will be performed within the HARMONY Alliance with support of Work Package 6.

Data protection

The personal data of participants (name, home country and email address) will be stored only for the duration of the survey on a secure server provided by the DelphiManager. After completion of the survey all data will be deleted.

By registering, all participants provide consent to the terms of the Delphi survey and they agree to the use of their data in the way described in the survey protocol.



Selection of the outcome list for WM

The empirical basis for identifying a list of preliminary MPN outcomes for the Delphi study so far has been threefold a two-step process:

First – A literature research was conducted in the COMET database to get an overview of the outcomes already used in existing clinical trials (10). The primary outcomes list was generated by extracting outcomes from the published literature (3-6).

Second – in order to include the patients’ perspective, patient advocates and people who have or have had MPN were invited to complement the preliminary list of outcomes by including additional outcomes and revise the list in accordance with their comments. In addition a specific literature research for patient-reported outcomes in MPN-patients was performed and included in the preliminary list (11).

D. DELPHI PROCESS

The preliminary MPN outcome list created after the process described above ([Annex 1](#)), will be used in the Delphi survey in a representative pool of stakeholders to agree in a pre-defined and iterative process on a COS for MPN.

The Delphi survey will include two rounds. In each round, the stakeholders will be asked to rate the importance of each outcome based on their personal experiences. Each outcome will be ranked into three categories (1-3 “not important”, 4-6 “important but not critical” and 7-9 “critical”) using a Likert scale of 1 to 9. After the completion of the first round of the Delphi survey no new participant will be invited.

Based on the experience of the previous harmony surveys, the surveys planned now will be held as a so-called “hackathon”.

For this purpose, a virtual meeting will take place on at least two days - this is also due to the current pandemic situation.

At these meetings, the surveys will be conducted in parallel by all participants. A major advantage of this is that any questions that arise can be asked and answered directly and, if necessary, support can be offered.

Within the questionnaire, outcomes will be grouped into domains so similar or related outcomes can be viewed and rated together. Each outcome will be described in plain language. Plain language descriptions are used from lists provided by patient advocates and also from native speakers with medical background.



When registering, participants will be asked which stakeholder group he/she belongs to. Once the individual participant has completed the first ranking round, he/she will also be able to provide additional feedback, by suggesting additional outcome parameters, which might be added within the subsequent Delphi rounds. This additional outcome will be added to the following Delphi rounds when two or more participants proposed this outcome to be included.

After each round, all participants will be provided with their own answers and an anonymized summary of the other participants' answers across all different stakeholder groups, in terms of the percentage scoring each of 1 to 9 on a particular outcome. Thereby feedback is provided from all stakeholder groups separately.

This allows the participants to revise their answers during the next round of the Delphi survey by taking the previous round's results into account. No outcome will be dropped out, so the participants can revise their initial ranking. The range of answers should decrease from round to round and a consensus opinion result, a core outcome set is defined. The process is stopped after pre-defined consensus criteria as described below.

After the final round a face-to-face consensus meeting will take place to finally discuss the results and to reaffirm the defined COS.

It will be important that as many participants as possible complete every round of the Delphi survey to ensure robust results of high representativeness.

The rate of non-response after the Delphi rounds, so called attrition is often highly variable. The attrition rate described over different Delphi studies varies from 0% to 20%. There is no recommendation regarding attrition rates, however an acceptable response rate would be 80%. To increase the response rates personalized email reminders will be sent out.

Attrition bias may occur if participants give no response to subsequent rounds of survey. Little evidence is available regarding the extent to which attrition bias influences the Delphi result.



E. RESULTS AND ANALYSIS

To reduce potential bias in the interpretation of the results a clear definition of consensus is crucial. There are three categories of consensus:

1. Consensus in

70 % or more respondents over all the respondents (clinicians, EFPIA members, regulators/HTA, patients and patient advocates) scored the outcome as critically important (7-9) AND 15% or fewer rate the outcome as limited important (1-3)

2. Consensus out

70 % or more of all the respondents (clinicians, EFPIA members, regulators/HTA, patients and patient advocates) scored the outcome as limited important (1-3)
AND 15 % or fewer rate the outcome as critically important (7-9)

3. No consensus

Outcomes that do not achieve a consensus through the several rounds in the Delphi survey.

After completing the last Delphi round, each participant will be asked about willingness to participate in a final meeting, representatives from all stakeholder groups will be part of this meeting.

The analysis of the Delphi study described in this protocol will use descriptive statistics. The results for each of the Delphi rounds, for each outcome and for each stakeholder group, will be presented in frequency tables. Quantitative analysis of the Delphi survey include calculations of i) percentage of panel's response rates and ii) percentages of responses in each of the three importance categories (1-3: "not important", 4-6: "important but not critical" and 7-9: "critical" based on 9-point Likert scale) for each outcome.

The data will be also displayed graphically, e.g., using histograms, for each stakeholder group and for each outcome. The plots will be reproduced for each round to further visualize the stability of the panel's opinion.

The analysis of the Delphi study will be performed using the R statistical software version 3.5.2. As mentioned above the exploratory analysis of the outcomes considered as important for patients will be analyzed as following: The median Likert score for the patient group at the end of each round will be calculated and those outcomes achieving a median of greater or equal to 7 (≥ 7) will be considered as important to patients.



F. STRENGTH & LIMITATIONS

As mentioned above different stakeholder groups take part in the Delphi survey. To ensure the impact of the highly important patient involvement in this process, a further specific category was added, called “patient important”. Thereby outcomes with a special interest for patients can be marked and emphasized in analysis.

The language used in the Delphi survey is English. This limits the group of people to participate in the Delphi to persons who do speak English. This might introduce a bias with regard to the countries participating in the Delphi, with e.g., a potential overrepresentation of English-speaking countries. While it was considered to translate the questionnaires into other European languages, this could pose additional problems and might introduce a different bias, e.g., depending on quality of the translations or depending on the number of participants per language, to name only a few.


To date, there is no recommendation found in literature regarding the number of participants to include in a Delphi survey. For certain stakeholder groups, for example for regulators it may be hard to recruit a large number of participants, which may lead to an imbalance of group size. With providing summarized results for each stakeholder group separately, the effect of inequitable distribution of group size is minimized, as described by COMET (13).

G. OUTLOOK

The anticipated way of developing the COS ensures that clinicians, industry, health authorities, as well as patients and patient advocates are involved in each stage of the development. In addition, the Delphi survey helps to make sure that the COS represents the priorities of all stakeholders. Ultimately, utilization of the COS will improve the relevance of trial endpoints to all stakeholders. Furthermore, it will increase the capacity for data synthesis between different trials.


In parallel to the completion of the Delphi survey in MPN, it is intended to start Delphi surveys to define a COS for the remaining hematological malignancies included in HARMONY Plus.

Finally, based on the results of the COS definition for the hematological malignancies included in HARMONY and HARMONY Plus a standardized COS applicable for all HMs will be created.




ANNEX 1 | PRELIMINARY OUTCOME LIST FOR MPN


Outcome	HelpText	DomainName	DomainName - simplified
Pain	Unpleasant physical sensation, including aching joints, which may vary in intensity from mild discomfort to pain that limits activities of daily life, limits self care and/or requires medication or hospitalisation. Medication may be necessary	PRO / HR-QoL - general - non-clinical	PRO
thrombosis / thromboembolism	a blood clot that forms a vein, results in pain or embolisms, thrombosis broke up and travelled e.g. to the lung, that results in dyspnea or ultimately death	PRO / HR-QoL - general - non-clinical	PRO
bleeding	blood loss	PRO / HR-QoL - general - non-clinical	PRO
Diarrhea / Constipation	Passing looser stools (poo) or passing stools more often than is normal for you or having difficulty passing stools (poo), which may be small and hard	PRO / HR-QoL - general - non-clinical	PRO
Nausea	Feeling or being sick, which may lead to impact on intake of food and/or fluids and/or normal activities	PRO / HR-QoL - general - non-clinical	PRO
Changes in taste and smell	Loss of the senses of smell and taste, including the reduced ability to smell or taste specific substances, for instance, sweet, sour, bitter or salty	PRO / HR-QoL - general - non-clinical	PRO
Anorexia	Loss of appetite, which may lead to weight loss and malnutrition	PRO / HR-QoL - general - non-clinical	PRO




Fatigue	Significant or persistant tiredness that's not proportional to recent activity	PRO / HR-QoL - general - non-clinical	PRO
Shortness of breath (Dyspnoea)	Shortness of breath or respiratory problems, which may happen at rest and may limit activities of daily living or self care, and may require treatment	PRO / HR-QoL - general - non-clinical	PRO
Change in sexual function	Such as changes in sexual desire, sexual dysfunction, erectile dysfunction, difficulties reaching orgasm, vaginal dryness in women, other genital changes that lead to pain during sexual activity, difficulty feeling arousal and pleasure during sex	PRO / HR-QoL - general - non-clinical	PRO
Infertility	Inability to get pregnant or to produce healthy sperms	PRO / HR-QoL - general - non-clinical	PRO
Hair loss	Alopecia or baldness, loss of hair from part of the head or body	PRO / HR-QoL - general - non-clinical	PRO
Sleep changes	Finding it difficult to get to sleep or to stay asleep	PRO / HR-QoL - general - non-clinical	PRO
Anxiety	Feelings of constant worry, or deep concern or uneasy about uncertainties	PRO / HR-QoL - general - non-clinical	PRO
Depression	Feelings of severe sadness and unhappiness, often with decreased energy, constant feelings of guilt, doubt or self-blame, worthlessness and hopelessness	PRO / HR-QoL - general - non-clinical	PRO
Blood transfusion dependence	transfusion of red blood cells and platelets is necessary	PRO / HR-QoL - general - non-clinical	PRO




Increased appreciation of life	positive change of attitudes towards life in general	PRO / HR-QoL - general - non-clinical	PRO
Good QOL interval (GQI)	Time frame a patient is experiencing good adequate QOL (according to their subjective interpretation using PRO's or answers from QOL tools)	PRO / HR-QoL - general - non-clinical	PRO
Psychosocial function	Problems with mental processes of perception, memory, judgment, reasoning or thinking with an effect on relationships with partner, family and friends including ability to join in with social activities	PRO / HR-QoL - PRO domains	PRO
Physical function	The effect of MPN or its treatment on day to day physical activities; for example, walking, climbing stairs, driving	PRO / HR-QoL - PRO domains	PRO
Role function	The effect of MPN or its treatment on your role; for example, ability to look after children or to work or earn money	PRO / HR-QoL - PRO domains	PRO
Financial toxicity	Financial losses because of co-payment for medical treatment, and if a patient was working before disease diagnosis or progression, loss of salary during sick leave, which may include leave taken by a carer	PRO / HR-QoL - PRO domains	PRO
Cost of MPN treatment and care	Money which must be spend on MPN treatment and also additional costs such as taxis or car park costs.	Health resource utilization - resource use	resource use



Need of caregiver assistance	Requirement for assistance given by caregiver (who could be a family member, friend or a professional care giver) in or outside the hospital	Health resource utilization - resource use	resource use
Independent living	Ability to live independently, without reliance on carers for daily routine tasks, self-care, trips to hospital or clinical staff house visits	Health resource utilization - resource use	resource use
Complete Response - CR (complete remission)	MPN gets better, resulting in no residual myeloblasts in bone marrow and normal peripher blood cells	Clinical outcome - Event type	type of event
reduction of systemic symptoms	improved condition due to fewer effects of the disease	Clinical outcome - Event type	type of event
Response - Stable disease (SD)	MPN stays the same after treatment. It is not getting better or worse	Clinical outcome - Event type	type of event
Relapse - Clinical relapse	Symptomatic return of MPN after a patient initially responds well to treatment	Clinical outcome - Event type	type of event
Cause of death	Death for any reason, whether related to MPN or not. This records the specific reason for death, not the time until death	Clinical outcome - Event type	type of event
Overall survival (OS)	Length of time that a patient remains alive from either the date of diagnosis or the start of treatment for the MPN	Clinical outcome - Time to event	time to event
Progression free survival (PFS)	Time until someone's MPN either gets worse or they die from any cause	Clinical outcome - Time to event	time to event
Relapse free survival (RFS)	Time until someone's MPN either gets worse, they die from any cause or they stop their	Clinical outcome - Time to event	time to event




	treatment because of side-effects		
Duration of response (DOR)	Length of time from responding positively to a treatment to the MPN starting to recur / to get worse	Clinical outcome - Time to event	time to event
Time to progression (TTP)	Time until someone's MPN recurs / gets worse (excluding death)	Clinical outcome - Time to event	time to event
Time to response (TTR)	Time from starting a treatment until a positive response to treatment is documented	Clinical outcome - Time to event	time to event
Time to treatment (TTT)	Time until first treatment is necessary	Clinical outcome - Time to event	time to event
Treatment free interval (TFI)	Time from the end of the treatment until the next therapy is needed	Clinical outcome - Time to event	time to event
Time to transformation	Time until MPN transforms in a acute myeloid leukemia	Clinical outcome - Time to event	time to event
Infection free interval (IFI)	Time frame a patients lives between 2 bouts of infections (without hospitalisations, antibiotics, anti-fungal or anti-viral treatment)	Clinical outcome - Time to event	time to event
Use of Granulocyte colony-stimulating factor (G-CSF) or erythropoiesis-stimulating agents (ESAs)	Treatment given to help a patient to make a certain type of white blood cell called a neutrophil or red blood cells called erythrocytes that is sometimes reduced in number because of treatment given or the patient's MPN	Clinical outcome - clinical parameter	clinical parameter



Transfusion independence	No need for regular transfusions of red blood cells or thrombocytes	Clinical outcome - clinical parameter	clinical parameter
Minimal residual disease (MRD) molecular	The level of MPN that can be detected as measured by using a DNA sequencing technique	Clinical outcome - MRD	clinical parameter
AEs (adverse events) and SAEs (serious adverse event)	A negative event or side-effect that happens during or after treatment, a clinical decision classified according to the latest "Common Terminology Criteria for Adverse Events", a descriptive terminology of adverse events. For each adverse event there is a grading for severity	Safety outcome - AE / Toxicity	Safety concerns
Medication adherence	Patients take their medication as prescribed by the doctor	Safety outcome - AE / Toxicity	Safety concerns
Discontinuation of treatment	Patient decides to stop treatment themselves or under the direction of his/her doctor for any reason other than finishing a course of treatment	Safety outcome - AE / Toxicity	Safety concerns
Hematological toxicity	Side-effects that cause changes in the blood or number of blood cells (e.g. anemia, leukopenia, thrombocytopenia, among others)	Safety outcome - AE / Toxicity	Safety concerns
Non-Hematological toxicity	Side-effects that cause changes anywhere other than in the blood, e.g. nausea, neuropathy, mucositis, renal or liver failure, infections	Safety outcome - AE / Toxicity	Safety concerns
Tolerability related outcomes	Measurement of how well patients are able to manage side-effects and whether they	Safety outcome - AE / Toxicity	Safety concerns




	need to reduce dose or stop treatment as a result		
Second primary malignancies (SPM)	A new cancer occurring in someone who has had a cancer in the past. It is different to recurrence, which is where the original cancer has returned	Safety outcome - AE / Toxicity	Safety concerns



ANNEX 2 | REFERENCES

- (1) <https://www.harmony-alliance.eu>
- (2) [HARMONY PLUS - HARMONY Alliance \(harmony-alliance.eu\)](https://www.harmony-alliance.eu)
- (3) Barbui T et al. The 2016 classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018. 8(2)
- (4) Loscocco G et al. Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data. Onco Target Ther. 2020. 13
- (5) Mughal TI et al. Recent advances in the genomics and therapy of BCR/ABL1 positive and negative chronic myeloproliferative neoplasms. Leuk Res. 2018. 6(7)
- (6) Economides MP et al. Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Curr Hematol Malig Res. 2019 14(5)
- (7) Kirkham JJ et al. Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement. Trials 2019 20(116)
- (8) Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, et al. (2017) Core Outcome Set-STANDARDS for Development: The COS-STAD recommendations. PLOS Medicine 14(11)
- (9) [COMET Initiative | Home \(comet-initiative.org\)](https://www.comet-initiative.org)
- (10) Research [COMET Initiative | Home \(comet-initiative.org\)](https://www.comet-initiative.org) on 31.12.2021
- (11) Petruk C, Mathias J. The Myeloproliferative Neoplasm Landscape: A Patient's Eye View. Adv Ther 2020. 37(5)
- (12) Williamson PR, et al., The COMET Handbook: version 1.0. Trials, 2017. 18 (Suppl 3): p. 280



The HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts to boost pharmaceutical innovation in Europe.

www.harmony-alliance.eu

HARMONY Communications Office

European Hematology Associations (EHA), The Hague, The Netherlands

– communications@harmony-alliance.eu

HARMONY Coordination Office

Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain

– harmonyoffice@ibsal.es

The HARMONY Alliance makes no warranties or representations of any kind as to the content's accuracy, currency, or completeness. Neither the HARMONY Alliance nor any party involved in creating, producing or delivering this document shall be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of or inability to use this document, or any errors or omissions in the content thereof. This material may not be used for commercial purposes. Remixing is not permitted except for private use.